Neuronetics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuronetics, Inc. on March 11, 2021, covering the event date of March 8, 2021. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol STIM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a personnel change and does not contain financial statements.
Material Changes
The material change reported is the departure of a senior officer:
- Gregory Harper, Vice President of R&D and Clinical, notified the Company of his intent to retire effective March 31, 2021.
- A three-month consulting agreement is intended to facilitate the transition of his responsibilities.
- Compensation under the consulting agreement is set at $200 per hour, plus reimbursement of expenses.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, or specific risk factors beyond the operational impact of the officer's departure.
Investor Verification Checklist
- Confirm the effective retirement date of Gregory Harper (March 31, 2021).
- Verify the terms of the proposed three-month consulting agreement.
- Monitor subsequent filings for the appointment of a replacement for the Vice President of R&D and Clinical role.